Trinity Life Sciences, a leader in global life sciences commercialization solutions, maps out investment strategies and tactics to calibrate a patient-centric approach in rare disease in its new advis...
New Advisory Brief Discusses Four Pillars to Focus Resource Allocation, Improve Patient Care and Provide Differentiated Patient Partnership
WALTHAM, Mass.: Trinity Life Sciences, a leader in global life sciences commercialization solutions, maps out investment strategies and tactics to calibrate a patient-centric approach in rare disease in its new advisory brief. The brief outlines four pillars that focus resource allocation, improve patient care and provide differentiated patient partnership. Within the nuances of each disease, companies must effectively address challenges around identifying and treating patients—as well as providing long-term support.
The advisory brief available today discusses four key pillars life sciences executives can leverage to achieve positive outcomes for patients:
“Rare disease brands face challenges that are different from mainstream therapies and have to find new ways of working to achieve positive outcomes,” explained Jennifer Parr, Partner and Head of Patient Centricity at Trinity Life Sciences. “Strategies and tactics need to be adapted to each disease to evolve the current patient journey and direct resource allocation in the most impactful ways.”
Challenges and solutions regarding each of the four pillars are discussed in a new advisory brief, entitled Calibrating a Patient-centric Approach in Rare Disease: Four Pillars to Focus Resource Allocation. By focusing on the strategies and tactics outlined in the advisory brief, manufacturers in the rare disease space can:
Life sciences executives are welcome to download the advisory brief here.
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With over 25 years of experience, Trinity is committed to revolutionizing the commercial model by providing exceptional levels of service, powerful tools and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.
Contacts Media Contact:
Elizabeth Marshall
Trinity Life Sciences
emarshall@trinitylifesciences.com
Fonte: Business Wire
Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…
G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes
Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries
Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…
$III #AI--Growing and evolving security threats make it increasingly important for enterprises to deploy advanced cybersecurity software and to understand…
Team8 a global venture fund that builds and invests in companies across cybersecurity, data, AI, fintech, and digital health, as well as their intersections…
Mitsubishi Electric Corporation (TOKYO: 6503) announced today that its ME Innovation Fund has invested in Things, Inc., a Japan-based startup that develops…
#BrianTepfer--PropStream, a leading real estate data and analytics platform and company in the Stewart Information Services Corporation family of companies…